Drug intelligence / Profile preview

enoxaparin + aspirin

Development stage
Phase 4
Lead developer
Sanofi
Modality
Small Molecules
Administration
Subcutaneous, Oral, Intravenous
01

Overview

Enoxaparin + aspirin is a combination therapy consisting of enoxaparin, a low molecular weight heparin anticoagulant, and aspirin (acetylsalicylic acid), an antiplatelet agent. This combination is used primarily to prevent complications from acute coronary syndromes such as unstable angina and heart attacks. Enoxaparin works by inhibiting factor Xa and IIa (thrombin), thereby reducing the formation of blood clots, while aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) in platelets, preventing the formation of thromboxane A2 and thus platelet aggregation. The dual action provides enhanced protection against clot formation but also increases the risk of bleeding complications, particularly gastrointestinal bleeding. This regimen is often used in hospital settings for patients with acute coronary syndromes or at high risk for thromboembolic events[2][4][5][9].

Other names
Enoxaparin with Aspirin
02

Targets

ATIII (Antithrombin III)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)F10 (Factor Xa)F2 (Thrombin)

Beyond the preview

Go deeper on enoxaparin + aspirin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on enoxaparin + aspirin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call